-
Huihe Healthcare Secures Hundreds of Millions in Series C1 and C2 Financing
•
Shanghai-based Huihe Healthcare, an interventional medical device maker for heart diseases, reportedly raised “hundreds of millions” of renminbi in Series C1 and C2 financing rounds. Guotai Junan Innovation Investment led the former while Shanghai Science and Technology Innovation Center Equity Investment Fund led the latter. The funding rounds included contributions…
-
Chaomu Technology Raises Series A+ Funding for Eye Disease Treatments
•
China-based eye disease treatment technology company Chaomu Technology (Beijing) Co., Ltd reportedly raised close to RMB 100 million (USD 14.3 million) in a Series A+ financing round led by InnoStar Capital. Mingheng Industrial Investment and Zhongzhi Zhonghe Technology Consulting Center also took part in the funding, proceeds of which will…
-
MaxHealth Biotechnology Completes Series B+ Financing Round
•
Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round at RMB 200 million (USD 28.64 million), led by GF Qianhe Investment. Other investors included existing investors China Life Private Equity Investment, and Wuxi Xinshang Investment, alongside new investors LongRiver Investments, Sealand Innovation, and Guangdong…
-
MicuRx Pharmaceuticals Gains Clinical Trial Approvals for MRX-4 in Europe
•
Sino-US firm MicuRx Pharmaceuticals Inc. announced receiving clinical trial approvals in France, Greece, Hungary, Italy, Latvia, Lithuania, Portugal, Spain, and Estonia for its novel anti-microbial agent MRX-4 combined with contezolid (MRX-I) as a sequential treatment for diabetic foot infection. Drug Overview and DevelopmentBoth drugs are in-house developed new-generation oxazolidinone antibiotics.…
-
F-Star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Again
•
UK-based F-Star Therapeutics Inc., (NASDAQ: FSTX) revealed that there has been yet another delay to its proposed takeover by Sino Biopharmaceutical Ltd (HKG: 1177) subsidiary invoX Pharma. The proposed USD 161 million acquisition of F-Star by Sino Bio has attracted the attention of the US Committee on Foreign Investment to…
-
ST Phi Therapeutics Partners with Azenta Life Sciences to Advance Cell Therapy
•
Hangzhou-based cell therapy specialist ST Phi Therapeutics struck a partnership with US firm Azenta Life Sciences (NASDAQ: AZTA) to bolster the development of industrial cell pharmaceutical enterprises. No financial details were disclosed. Company Background and CapabilitiesFounded in 2018, ST Phi Therapeutics boasts its 3,600-square-meter GMP-compliant research and development center and…
-
Beijing Wantai’s Nasal Spray COVID-19 Vaccine Approved for Emergency Use in China
•
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced the inclusion of its nasal spray influenza virus vector SARS-CoV-2 vaccine co-developed by Xiamen University and Hong Kong University, in the emergency use program in China. Vaccine Development and MechanismThe vaccine, produced by inoculating Madin-Darby Canine Kidney (MDCK) cells…
-
Everlife Biomed Raises Pre-Series A+ Funding for Immune Exemption Platform
•
Beijing-based Everlife Biomed reportedly raised “tens of millions” of renminbi in a pre-Series A+ financing round led by Redhill Capital. Other investors included Ruisheng Equity Investment and Yuanhe Capital. Proceeds will go toward safety validation for its core pipelines, process development and clinical filings, manufacturing plant expansion, and talent recruitment.…
-
MicroPort MedBot’s Orthopedic Surgery Robot Receives CE Certification
•
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced receiving a CE certification in Europe for its in-house developed orthopedic surgery robot Honghu, the first and only domestically-developed surgical robot approved in the region. The Sky Walker knee joint navigation and positioning system was previously approved for marketing in China…
-
Junshi Biosciences Files for EMA Approval of Tuoyi for Nasopharyngeal and Esophageal Cancers
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that a market approval filing has been made for its programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) with the European Medicines Agency (EMA). The biotech is seeking approval for the checkpoint inhibitor in combination with chemotherapy as a first-line treatment for locally recurrent…
-
Akeso Biopharma Plans IPO on Shanghai’s STAR Market
•
China-based antibody developer Akeso Biopharma (HKG: 9926) announced that its board of directors has decided to make an initial public offering (IPO) to the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). No formal filing has been made at this stage. Company Background and PlatformFounded in 2012, Akeso Bio boasts an…
-
Tonghua Dongbao Licenses Biosimilar Victoza to Kexing for Emerging Markets
•
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced a licensing agreement with compatriot firm Kexing Pharmaceutical (SHA: 688136), granting the latter exclusive commercialization rights to its biosimilar version of Novo Nordisk’s Victoza (liraglutide) in 17 emerging markets (EMs). Victoza: Background and ApprovalVictoza, a human glucagon-like peptide-1 (GLP-1) analogue, was first approved…
-
WestVac Biopharma’s Recombinant COVID-19 Vaccine Approved for Emergency Use in China
•
Chengdu-based WestVac Biopharma Co., Ltd announced the inclusion of its recombinant COVID-19 vaccine (Sf9 cells) in the emergency use program in China. It is the first recombinant protein novel coronavirus vaccine produced by the insect cell technology platform approved for emergency use in China. Vaccine Efficacy and TechnologyThe data shows…
-
Qilu Pharmaceutical’s QL1604 Plus Chemotherapy Shows Promise in Phase II Study
•
China-based Qilu Pharmaceutical announced that the results of the Phase II study assessing its QL1604 plus chemotherapy as a first-line treatment for patients with recurrent or metastatic (R/M) cervical cancer were released on December 4, 2022, in an oral presentation (Proffered Paper, 179O) at the European Society for Medical Oncology…
-
China Health Group Signs Framework Agreement with Mingcheng Wanda Pharma
•
China Health Group Ltd (HKG: 0673) announced the signing of a framework agreement with compatriot firm Wuhan Mingcheng Wanda Pharmaceutical Co., Ltd, seeking to carry out close collaboration on the comprehensive distribution of medical and big health products. The two sides are working on specific transaction terms, and an official…
-
Hybio Receives Ethical Approval for HY3000 COVID-19 Nasal Spray Phase II Study
•
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced receiving ethical approval for a Phase II clinical study protocol for its Category 1.1 chemical drug HY3000 nasal spray targeting COVID-19. The clinical filing for the product was accepted for review by the National Medical Products Administration (NMPA) in August 2022. Study…
-
Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Included in China’s Emergency Use Program
•
China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced the inclusion of its COVID-19 vaccine SCB-2019 (CpG 1018/Alum) in the emergency use program in China. The protein vaccine was developed using Clover’s proprietary Trimer-Tag (protein trimerization) technology, a drug development platform which allows the production of novel, covalently-trimerized fusion proteins.…
-
Microport EP Medtech’s Pressure Monitoring Catheter Approved by NMPA
•
Shanghai Microport EP Medtech Co., Ltd’s disposable pressure monitoring magnetic positioning radiofrequency catheter has been approved for marketing by the National Medical Products Administration (NMPA), marking the 185th innovative medical device in China. Product Features and BenefitsThe product adopts pressure sensing technology based on the principle of strain gauge, magnetic…
-
Henlius Biotech Doses First Patient in Phase I Study for HLX60 in China
•
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing of a Phase I clinical study for its HLX60 in solid tumors and lymphomas in mainland China. Study Design and ObjectivesThe open, dose escalation, first-in-human Phase I study is designed to assess the safety and tolerability of the drug…
